BioSpace News Archive

Imvax, Inc., a clinical-stage biotechnology company developing personalized, whole tumor-derived immunotherapies, is presenting data on the activity of the company’s tumor-derived immunotherapies in glioblastoma and other solid tumors at the American Association for Cancer Research Annual Meeting 2022 in New Orleans, La.

Elpis Biopharmaceuticals, an IND stage biopharmaceutical company developing next generation immunotherapies to transform cancer treatment, today presented two posters at the American Association for Cancer Research (AACR) Annual Meeting, occurring April 8-13, 2022.

Orphagen Pharmaceuticals Inc., a biotech company pioneering the screening, discovery, and development of small molecule ligands that modulate orphan or unexplored members of the nuclear receptor family, today announced a late-breaking presentation of new preclinical data for OR-449 at the American Association for Cancer Research (AACR) Annual Meeting 2022 being held April 8-13 both virtually and in-person in New Orleans.

Orum Therapeutics, a private biotechnology company pioneering the development of tumor-directed targeted protein degraders (TPDs), today presented preclinical data for ORM-5029, a potential first-in-class TPD therapy for HER2-positive cancers, at the American Association for Cancer Research (“AACR”) Annual Meeting 2022.

Immune-Onc Therapeutics, Inc. (“Immune-Onc”), a private, clinical-stage cancer immunotherapy company developing novel biotherapeutics targeting myeloid checkpoints, today announced two poster presentations on its clinical stage program IO-108, a novel myeloid checkpoint inhibitor targeting Leukocyte Immunoglobulin-Like Receptor B2 (LILRB2, also known as ILT4), at the American Association for Cancer Research (AACR) Annual Meeting.

OncoOne, a biotechnology company focused on discovering precision medicines for cancer and autoimmune diseases, announced today the presentation of preclinical proof-of-concept data on its lead candidate ON203, a therapeutic monoclonal antibody targeting oxMIF, and the radiodiagnostic 89Zr-ON102, at the American Association for Cancer Research (AACR) Annual Meeting 2022, held from April 8-13, in New Orleans, Louisiana.

Scorpion Therapeutics, Inc. today announced preclinical proof-of-concept data for STX-478.

Repare Therapeutics Inc., a leading clinical-stage precision oncology company, announced it has been selected for an oral presentation of clinical data from its ongoing Phase 1/2 TRESR trial of RP-3500, a potent and selective oral small molecule inhibitor of ATR, as well as two additional poster presentations at the upcoming 2022 AACR Annual Meeting held in New Orleans on April 8-13, 2022.

Xencor Presents Data from Multiple Preclinical XmAb ® Cytokine Programs at the American Association for Cancer Research (AACR) Annual Meeting 2022.

Transgene will present additional positive immunogenicity and clinical data on TG4050, its individualized neoantigen cancer vaccine.